Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) to Post -$1.81 Earnings Per Share

Analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from ($2.28) to ($1.58). Alnylam Pharmaceuticals reported earnings of ($1.61) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 12.4%. The firm is scheduled to announce its next earnings results on Thursday, August 1st.

On average, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($7.41) per share for the current year, with EPS estimates ranging from ($8.42) to ($6.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($6.90) per share, with EPS estimates ranging from ($9.16) to ($4.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The firm had revenue of $33.29 million for the quarter, compared to analysts’ expectations of $21.60 million. During the same period in the previous year, the firm earned ($1.22) earnings per share. The business’s revenue was up 52.0% compared to the same quarter last year.

ALNY has been the topic of several research analyst reports. Morgan Stanley raised Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 target price on the stock in a research note on Tuesday, March 5th. ValuEngine lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. UBS Group initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 23rd. They set a “neutral” rating and a $87.00 price target on the stock. Evercore ISI initiated coverage on Alnylam Pharmaceuticals in a research report on Thursday, April 11th. They set an “outperform” rating and a $120.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, February 8th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $130.24.

In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the sale, the director now directly owns 250,633 shares of the company’s stock, valued at $22,113,349.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 332.9% in the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 263 shares in the last quarter. US Bancorp DE boosted its holdings in Alnylam Pharmaceuticals by 66.2% in the first quarter. US Bancorp DE now owns 369 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 147 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $47,000. Quadrant Capital Group LLC boosted its holdings in Alnylam Pharmaceuticals by 543.2% in the first quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 440 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co boosted its holdings in Alnylam Pharmaceuticals by 40.0% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 200 shares in the last quarter. 87.89% of the stock is currently owned by institutional investors and hedge funds.

ALNY opened at $68.73 on Tuesday. The company has a current ratio of 9.33, a quick ratio of 9.12 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals has a 52-week low of $60.27 and a 52-week high of $124.21.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

See Also: Trading based on a resistance level

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.